Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism
Not available.
Saved in:
| Main Authors: | Catherine Duane, Siobhan Glavey, John Quinn, Philip Murphy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11971 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to Comment on: “Targeted anti-cancer agents and risk of venous thromboembolism”
by: Melina Verso, et al.
Published: (2025-04-01) -
Venous Thromboembolism Risk Assessment Audit
by: Sunday Neru, et al.
Published: (2025-06-01) -
Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Maria I. Zervou, et al.
Published: (2025-02-01) -
Systemic hormonal contraception and risk of venous thromboembolism
by: Oskari Heikinheimo, et al.
Published: (2022-08-01) -
Risk of venous thromboembolism in patients with pancreatic cancer
by: O. I. Kit, et al.
Published: (2022-06-01)